Literature DB >> 15037082

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.

Akira Okazaki1, Emi Shoji-Hosaka, Kazuyasu Nakamura, Masako Wakitani, Kazuhisa Uchida, Shingo Kakita, Kouhei Tsumoto, Izumi Kumagai, Kenya Shitara.   

Abstract

Depletion of fucose from human IgG1 oligosaccharide improves its affinity for Fcgamma receptor IIIa (FcgammaRIIIa). This is the first case where a glycoform modification is shown to improve glycoprotein affinity for the receptors without carbohydrate-binding capacity, suggesting a novel glyco-engineering strategy to improve ligand-receptor binding. To address the mechanisms of affinity improvement by the fucose depletion, we used isothermal titration calorimetry (ITC) and biosensor analysis with surface plasmon resonance. ITC demonstrated that IgG1-FcgammaRIIIa binding was driven by favorable binding enthalpy (DeltaH) but opposed by unfavorable binding entropy change (DeltaS). Fucose depletion from IgG1 enhanced the favorable DeltaH, leading to the increase in the binding constant of IgG1 for the receptor by a factor of 20-30. The increase in the affinity was mainly attributed to an enhanced association rate. A triple amino acid substitution in IgG1, S298A/E333A/K334A, is also known to improve IgG1 affinity for FcgammaRIIIa. ITC demonstrated that the amino acid substitution attenuated the unfavorable DeltaS resulting in a three- to fourfold increase in the binding constant. The affinity enhancement by the amino acid substitution was due to a reduced dissociation rate. These results indicate that the mechanism of affinity improvement by the fucose depletion is quite distinct from that by the amino acid substitution. Defucosylated IgG1 exhibited higher antibody-dependent cellular cytotoxicity (ADCC) than S298A/E333A/K334A-IgG1, showing a correlation between IgG1 affinity for FcgammaRIIIa and ADCC. We also examined the effect of FcgammaRIIIa polymorphism (Val158/Phe158) on IgG1-FcgammaRIIIa binding. The Phe to Val substitution increased FcgammaRIIIa affinity for IgG1 in an enthalpy-driven manner with the reduced dissociation rate. These results together highlight the distinctive functional improvement of affinity by IgG1 defucosylation and suggest that engineering of non-interfacial monosaccharides can improve glycoprotein affinity for receptors via an enthalpy-driven and association rate-assisted mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037082     DOI: 10.1016/j.jmb.2004.01.007

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  104 in total

1.  Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314.

Authors:  Ralf Kircheis; Nicole Halanek; Iris Koller; Wolfgang Jost; Manfred Schuster; Gilbert Gorr; Klaus Hajszan; Andreas Nechansky
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.

Authors:  Mounia Sabrina Braza; Bernard Klein; Geneviève Fiol; Jean-François Rossi
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 3.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

Review 4.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

5.  Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.

Authors:  Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

7.  Characterization of Mauritian Cynomolgus Macaque FcγR Alleles Using Long-Read Sequencing.

Authors:  Amelia K Haj; Jaren M Arbanas; Aaron P Yamniuk; Julie A Karl; Hailey E Bussan; Kenneth Y Drinkwater; Michael E Graham; Adam J Ericsen; Trent M Prall; Kristina Moore; Lin Cheng; Mian Gao; Robert F Graziano; John T Loffredo; Roger W Wiseman; David H O'Connor
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

Review 8.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

9.  Post-translational modifications differentially affect IgG1 conformation and receptor binding.

Authors:  Damian Houde; Yucai Peng; Steven A Berkowitz; John R Engen
Journal:  Mol Cell Proteomics       Date:  2010-01-26       Impact factor: 5.911

10.  Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.

Authors:  Maria Carmen Ochoa; Luna Minute; Ascensión López; Elisabeth Pérez-Ruiz; Celia Gomar; Marcos Vasquez; Susana Inoges; Iñaki Etxeberria; Inmaculada Rodriguez; Saray Garasa; Jan-Peter Andreas Mayer; Peter Wirtz; Ignacio Melero; Pedro Berraondo
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.